Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SGK1 | O00141 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756196 | 0.84 | TACR3 (0.46) | LMNARAB9AMAPTNPC1MEN1 | |
| SCHEMBL2298250 | 0.81 | RAB9A (0.58) | LMNARAB9AMAPTNPC1MEN1 | |
| SCHEMBL2298245 | 0.81 | RAB9A (0.58) | LMNARAB9AMAPTNPC1MEN1 | |
| SCHEMBL1756253 | 0.81 | DGAT1 (0.47) | LMNAMAPTGAAALDH1A1 | |
| SCHEMBL1756202 | 0.78 | MEN1 (0.52) | LMNARAB9AMAPTMEN1KMT2A | |
| SCHEMBL11969065 | 0.78 | MEN1 (0.52) | LMNARAB9AMAPTMEN1KMT2A | |
| SCHEMBL1761789 | 0.78 | TAS1R3 (0.54) | LMNARAB9AMAPTNPC1MEN1 | |
| SCHEMBL1756223 | 0.77 | MEN1 (0.53) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL2294231 | 0.77 | CSGALNACT1 (0.54) | — | |
| SCHEMBL2294233 | 0.77 | CSGALNACT1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722901-B2 | Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity | Piramal Enterprises Limited (IN) | 2014-05-13 | — | — | US | disclosed |
| EP-2496564-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | Piramal Enterprises Limited (IN) | 2012-08-23 | — | — | US | disclosed |
| WO-2011055289-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | DGAT1, DGAT2, DLAT | LMNA 4085/4885RAB9A 3809/4885MAPT 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.